|drug2566||Placebo- 1.00 mg/kg Wiki||1.00|
|drug1103||Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg) Wiki||1.00|
|drug2564||Placebo- 0.10 mg/kg Wiki||1.00|
|drug1097||Drug: GS-5734 - 2.00 mg/kg Wiki||1.00|
|drug1100||Drug: NA-831 - 0.10 mg/kg Wiki||1.00|
|drug2567||Placebo- 2.00 mg/kg Wiki||1.00|
|drug1096||Drug: GS-5734 - 1.00 mg/kg Wiki||1.00|
|drug1101||Drug: NA-831 - 0.20 mg/kg Wiki||1.00|
|drug2565||Placebo- 0.20 mg/kg Wiki||1.00|
|drug1104||Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg) Wiki||1.00|
|drug2515||Placebo 0.10 mg + 1.00 mg/kg Wiki||1.00|
|drug2516||Placebo 0.20 mg + 2.00 mg/kg Wiki||1.00|
|D009410||Nerve Degeneration NIH||0.71|
|D012141||Respiratory Tract Infections NIH||0.18|
|D014777||Virus Diseases NIH||0.11|
There is one clinical trial.
The study aims to longitudinally track the onset, severity and recovery of changes in chemosensory acuity (smell and/or taste loss) among those suspected of COVID-19 infection. Using standardised questionnaire and testing approaches, the investigators aim to objectively characterise and measure temporal changes in taste and smell to confirm the prevalence of these symptoms as an early marker of infection. Information on symptoms experience, changes in appetite and food-related quality of life will be also be assessed via questionnaire. The results of the study will help individuals who experience a loss of smell and/or taste to self-isolate and/or self-refer to a medical professional, if an association between smell and/or taste and COVID-19 infection is found.
Description: Taste and smell functions of all participants will be assessed as part of the Home-use Test using taste test items (i.e. sweet: sugar, salty: salt, sour: lime powder and bitter: coffee powder) and odour pens respectively. Participants will identify the taste/smell and rate the perceived intensity on a Visual Analogue Scale (VAS) from 'not strong at all' (0) to 'extremely strong taste/smell' (100). A higher score will indicate greater intensity of taste/smell perceived.Measure: Taste and smell acuity Time: 28 days
Description: Experienced symptoms, changes in appetite and food-related quality of life will be assessed as part of the Follow-up questionnaire.Measure: Experienced symptoms, changes in appetite and food-related quality of life Time: 28 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports